US pharma group to pay €90.5mn for 8% in deal that will boost joint Lyme disease programme
Pfizer buys stake in French vaccine maker Valneva
Related Posts
Eli Lilly’s Potential Acquisition of Scorpion Therapeutics: A Strategic Shift Amid Market Volatility
Strategic Acquisition: Eli Lilly's potential acquisition of Scorpion Therapeutics signals a strategic move to bolster its oncology pipeline and enhance innovation capabilities. Biotech Market...
Biogen Bids for Sage Therapeutics: Boosting Neuroscience & Psychiatric Treatments
Strategic Rationale: Biogen's bid to acquire Sage Therapeutics' remaining stake aligns with its long-term strategy to expand neuroscience capabilities and strengthen its psychiatric and neurological...
GSK Acquires IDRx for $1.15B: A Precision Leap in GI Cancer Therapy
Strategic Expansion: GSK's $1.15B acquisition of IDRx bolsters its gastrointestinal (GI) cancer therapy portfolio, marking a significant expansion into the oncology market. Financial Details: The...
Johnson & Johnson Eyes $10B Neuroscience Drugmaker Acquisition: Strategic Move Amidst Market Growth
Strategic Alignment: The acquisition aligns Intra-Cellular's neuroscience pipeline with J&J's pharmaceutical offerings, positioning J&J for growth in the $48B neuroscience market. Market Potential:...